Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China.
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Front Immunol. 2022 Feb 14;13:766200. doi: 10.3389/fimmu.2022.766200. eCollection 2022.
Asparaginase/pegaspargase containing regimens combined with radiotherapy are highly effective and considered the cornerstone of localized Natural killer/T-cell lymphoma (NKTL) treatment. However, these chemotherapy regimens inevitably cause relatively high incidence of treatment-related adverse events (TRAEs). Herein we retrospectively evaluated the efficacy and safety of the combined regimen of anti-PD-1 antibody, anlotinib and pegaspargase "sandwich" with radiotherapy in localized NKTL. Anti-PD-1 antibody and pegaspargase at 2500 U/m were administered on day 1, while anlotinib (12 mg once a day) was orally administered on days 1-14. The treatment was repeated every 3 weeks. All the eight patients included received 3 cycles of the regimen followed by radiotherapy and an additional 3 cycles. The overall response rate was 100%, and the complete response rate was 87.5%. With a median follow-up time of 35.5 months (range, 34.03-40.90 months), median PFS and OS times were not reached. The 3-year PFS and OS rates were 100% and 100%, respectively. All patients were alive at the last follow-up. No treatment-related death and no grade 4 TRAE was reported. No grade 3/4 hematological toxicity was detected, and half of the patients didn't report any hematological toxicity. This study indicates that anti-PD-1 antibody combined with anlotinib and pegaspargase is a promising chemoradiotherapy regimen for localized NTKL, with mild toxicity and good tolerance.
含 asparaginase/pegaspargase 的方案联合放疗对局限性自然杀伤/T 细胞淋巴瘤（NKTL）的治疗具有高度疗效，被认为是其治疗基石。然而，这些化疗方案不可避免地会导致较高的治疗相关不良反应（TRAEs）发生率。在此，我们回顾性评估了抗 PD-1 抗体、安罗替尼和 pegaspargase“三明治”联合放疗治疗局限性 NKTL 的疗效和安全性。抗 PD-1 抗体和 pegaspargase 分别于第 1 天给药 2500U/m，安罗替尼（12mg/天，口服）于第 1-14 天给药。每 3 周重复治疗。所有 8 例患者均接受了 3 个周期的治疗方案，随后进行放疗和另外 3 个周期的治疗。总的缓解率为 100%，完全缓解率为 87.5%。中位随访时间为 35.5 个月（范围 34.03-40.90 个月），中位无进展生存期（PFS）和总生存期（OS）均未达到。3 年 PFS 和 OS 率分别为 100%和 100%。所有患者在最后一次随访时均存活。无治疗相关死亡，无 4 级 TRAE 发生。未检测到 3/4 级血液学毒性，半数患者未报告任何血液学毒性。这项研究表明，抗 PD-1 抗体联合安罗替尼和 pegaspargase 是一种有前途的局限性 NTKL 化放疗方案，具有良好的疗效和耐受性，毒性较低。
